Sunday 11 October 2026
Export all AZN data to Excel Powerpack
AstraZeneca PLC
AZN Healthcare Drug Manufacturers General
AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024. In the quarter to June 2026, revenue grew 6.41%, EPS grew 1.90%, free cash flow fell 107.5% and total debt fell 5.50%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five; insiders bought in the last twelve months.
159.20
0.42
+0.26%
Follow AZN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
21.66% | 22.83% | 23.47% | 21.95% | |
Piotroski F-Score |
7 | 8 | 9 | 8 | |
| 8.57% | 9.38% | 9.43% | 9.15% | ||
ROIC |
11.65% | 12.15% | 12.48% | 11.67% | |
Return on Tangible Assets |
117.93% | 92.38% | 102.21% | 104.18% | |
Average Days of Receivables |
95.15 | 101.50 | 91.58 | 95.10 | |
Free Cash Flow per Share |
6.25 | 2.84 | 5.13 | 4.04 | |
Free Cash Flow |
9,691.00 | 8,819.00 | 7,939.00 | 6,265.00 | |
Capital Expenditures |
(5,449.00) | (5,756.00) | (6,282.00) | (7,435.00) | |
| Other line items | |||||
Cash ROIC |
11.40% | 10.71% | 9.11% | 7.38% | |
Accounts Receivable Turnover |
4.05 | 3.77 | 4.03 | 3.94 | |
Accounts Payable Turnover |
0.44 | 0.45 | 0.49 | 0.47 | |
Inventory Turnover |
1.67 | 1.80 | 1.78 | 1.66 | |
Average Days of Payables |
892.11 | 867.79 | 742.03 | 751.43 | |
Days of Inventory on Hand |
235.00 | 225.08 | 216.63 | 227.53 | |
Tax Rate |
(0.18) | (0.17) | (0.20) | (0.17) | |
Research and Development Expense of Revenue |
25.89% | 24.23% | 24.10% | 24.56% | |
Selling, General and Administrative Expense of Revenue |
35.13% | 34.92% | 34.66% | 35.42% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
7.75 | 8.11 | 8.24 | 8.06 | |
Operating CF/Net income |
1.61 | 1.43 | 1.37 | 1.31 | |
Depreciation/Fixed assets |
0.54 | 0.44 | 0.44 | 0.47 | |
Capex/Depreciation |
(0.83) | (1.00) | (1.08) | (1.17) | |
Revenue per Share |
37.48 | 18.95 | 39.02 | 39.57 | |
Operating CF per Share |
9.76 | 4.70 | 9.18 | 8.83 | |
Capex per Share |
(3.51) | (1.86) | (4.06) | (4.79) | |
Capex to Sales |
0.09 | 0.10 | 0.10 | 0.12 |
Columns are period end dates